Resmed Inc
NYSE:RMD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
165.79
256.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Resmed Inc
Wall Street
Price Targets
RMD Price Targets Summary
Resmed Inc
According to Wall Street analysts, the average 1-year price target for
RMD
is 254.73 USD
with a low forecast of 191.9 USD and a high forecast of 297.15 USD.
RMD Last Price Targets
Resmed Inc
The latest public price target was made on Oct 1, 2024 by
Craig Wong-Pan
from
RBC Capital
,
who expects
RMD
stock to
drop by 3%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Craig Wong-Pan
RBC Capital
|
224
USD
Downside 3% |
2 months ago
Oct 1, 2024
|
ResMed (RMD) PT Raised to $224 at RBC Capital
StreetInsider
|
Joe Vruwink
Robert W. Baird
|
280
USD
Upside 21% |
3 months ago
Sep 23, 2024
|
Baird Starts ResMed (RMD) at Outperform
StreetInsider
|
Mike Polark
Wolfe Research
|
180
USD
Downside 22% |
3 months ago
Sep 18, 2024
|
Wolfe Research Downgrades ResMed (RMD) to Underperform
StreetInsider
|
|
Craig Wong-Pan
RBC Capital
|
187
USD
Downside 19% |
8 months ago
Apr 10, 2024
|
ResMed (RMD) PT Raised to $187 at RBC Capital
StreetInsider
|
Mike Matson
Stifel Nicolaus
|
224
USD
Downside 3% |
8 months ago
Apr 1, 2024
|
ResMed (RMD) PT Raised to $224 at Stifel
StreetInsider
|
Suraj Kalia
Oppenheimer
|
175
USD
Downside 25% |
1 year ago
Oct 27, 2023
|
How Sleep Device Player ResMed Is Gaining Philips' Market Share In Flow Generator Market - Analysts Weigh In
Benzinga
|
Mike Matson
Needham
|
180
USD
Downside 22% |
1 year ago
Sep 6, 2023
|
Needham & Company Upgrades ResMed (RMD) to Buy
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RMD's stock price target?
Price Target
254.73
USD
According to Wall Street analysts, the average 1-year price target for
RMD
is 254.73 USD
with a low forecast of 191.9 USD and a high forecast of 297.15 USD.
What is Resmed Inc's Revenue forecast?
Projected CAGR
8%
For the last 8 years the
compound annual growth rate for
Resmed Inc's revenue is
12%.
The projected
CAGR
for the next 3 years is
8%.
What is Resmed Inc's Operating Income forecast?
Projected CAGR
14%
For the last 8 years the
compound annual growth rate for
Resmed Inc's operating income is
16%.
The projected
CAGR
for the next 3 years is
14%.
What is Resmed Inc's Net Income forecast?
Projected CAGR
18%
For the last 8 years the
compound annual growth rate for
Resmed Inc's net income is
14%.
The projected
CAGR
for the next 3 years is
18%.
You don't have any saved screeners yet
